Serial Assessment of Immune Status by Circulating CD8+ Effector T Cell Frequencies for Posttransplant Infectious Complications
Figure 6
(a) Changes in % difference in CD8+ naive, CM, EM, and effector T cells, as well as IFN-, perforin, and CD27−CD28− subsets in a 62-year-old male recipient undergoing LDLT to treat HCV-related liver cirrhosis and hepatocellular carcinoma. Right, scatter plot between % E difference and % effector T cell
proportion. 1st phase is the period before Tac administration. 2nd phase is the period after Tac administration. Pre, pre-LDLT; Tac, tacrolimus; the number above black circles in right figure, postoperative days. Left figure: N, naive T cells; E, effector T cells; CM, central memory T cells; and EM, effector memory T cells. Middle figure: IFN-, interferon-gamma; and CD27−CD28−, CD27−CD28− subsets. (b) Posttransplant changes in % difference in CD8+ T cell subsets as well as IFN-, perforin, and CD27−CD28− subsets in a 60-year male recipient undergoing to treat HBV-related liver cirrhosis and hepatocellular carcinoma. Right, Scatter plot between % E difference and % effector T cell proportion. 1st phase is the period before Tac administration. 2nd phase is the period after Tac administration. Pre, pre-LDLT; Tac, tacrolimus; HAI, hepatic artery flow interruption; Bx, biopsy; the number above black circles in right figure, postoperative days.
